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system, which can lead to disparities in treatment. METHODS:
Using nationally representative data from the Medicare Current
Beneﬁciary Survey, 1992–2003 and the Medical Expenditure
Panel Survey, 1999–2003, we estimated the out-of-pocket prices
for common opioid analgesics among community-dwelling
adults in theUnited States. Standardized gamma mixture models
were estimated to predict out-of-pocket prices for individuals
with and without drug coverage controlling for setting charac-
teristics, such as year, as well as prescription speciﬁc attributes
such as number of tablets and controlled release form.
RESULTS: Typical prescription for opioid analgesics costs a
patient between $6.20 and $64.17, if they have drug coverage,
and between $16.22 and 134.60 without coverage. CONCLU-
SION: A better understanding of the endogeneity of out-of-
pocket prices not only improves our ability to identify the
demand for health care, these models better characterize the
ﬁnancial burden of pain management.
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OBJECTIVES: To identify lower back pain (LBP) patients who
use narcotic medications and examine their medication behav-
iors, medical and pharmacy claim costs and associated comor-
bidities. METHODS: This study used medical and pharmacy
claims data from 165,569 employees’ ages 18 to 64 years from
three employer groups from September 2002 to December 2003.
LBP patients were identiﬁed using ICD-9 diagnosis codes from
medical claims data. Differences in costs and comorbidities were
examined between LBP patients who use narcotic medications
and LBP patients who do not use narcotic medications.
RESULTS: Among eligible members, 13,760 (8.3%) were iden-
tiﬁed as LBP patients. Nearly 60% were female with an average
age of 46.8 years. Approximately half of the LBP patients
(44.8%) used narcotic medications; however, they consumed
71% of total health care costs (medical plus pharmacy costs)
among LBP patients. The average monthly total health care cost
for a narcotic-using LBP patient was $1,040 versus $347 for a
LBP patient without narcotics. Narcotic-using LBP patients had
signiﬁcantly (p < 0.001) higher rates of comorbid conditions than
LBP patients without narcotic use: hypertension (22.9% vs.
13.3%), arthritis (14.1% vs. 4.3%), diabetes (10.4% vs. 5.6%),
asthma (7.4% vs. 4.0%), coronary artery disease (5.0% vs.
2.5%), depression (10.3% vs. 5.4%) and anxiety (6.3% vs.
2.8%). Also, LBP patients with comorbid anxiety or depression
on average used more narcotic medications than patients with
other comorbidities. LBP patients who use narcotic medications
are also more likely to visit the emergency room, use physical
therapy or chiropractic services, utilize one or more epidurals
and/or MRI’s, or have a surgery (p < 0.001). CONCLUSION:
Lower back pain patients who use narcotic medications are more
likely to have additional health conditions and higher health care
costs than non-narcotic using LBP patients. Further, patients
with comorbid anxiety or depression take more narcotics than
those with other comorbidities.
PPN10
COSTS ATTRIBUTABLE TO INTRAVENOUS PATIENT
CONTROLLED ANALGESIA: FOCUS ON 
DEVICE-RELATED EVENTS
Nelson WW1, Meissner BL1, Gagne JJ2, Schein JR3
1Xcenda, Palm Harbor, FL, USA, 2Thomas Jefferson University,
Philadelphia, PA, USA, 3Ortho-McNeil Janssen Scientiﬁc Affairs, LLC,
Raritan, NJ, USA
OBJECTIVES: To estimate the costs of device-related events
associated with intravenous patient-controlled analgesia (IV
PCA) from the perspective of a hospital or integrated health-
system. METHODS: To estimate the costs attributable to both
harmful and non-harmful IV PCA device-related events, a quasi-
cost accounting methodology is utilized. Data were obtained
from the Manufacturer and User facility Device Experience
(MAUDE) dataset, published literature, and expert opinions.
The MAUDE dataset is publicly available, and contains manda-
tory FDA reports of medical device-related events. IV PCA event
reports were identiﬁed from the MAUDE database (January 1,
2002-December 31, 2003) and the descriptive text was qualita-
tively reviewed to collect data on event consequences. The level
of care rendered for the event consequences was estimated by
applying clinical assumptions validated by an expert advisory
panel. Both variable and opportunity costs (2006 values) were
considered, including medication, laboratory, lost revenue, and
labor. Whenever an event consequence was indicated in a report,
the corresponding costs were applied to derive the estimated
mean cost for each event type. The event types were previously
deﬁned and published (Device Safety Events, Operator Errors,
Adverse Reactions to Opioids, Patient-related Events, and Inde-
terminate Events). RESULTS: The most costly event type was
Adverse Reactions to Opioids, followed by Operator Errors
(mean costs of $13,803 and $2,955 respectively). When strati-
ﬁed, events reported to be harmful to patients were associated
with higher costs than non-harmful events: $3483 vs. $0 for
Device Safety Events, $5756 vs. $361 for Operator Errors, $199
vs. $11 for Patient-related Events, and $6120 vs. $142 for Inde-
terminate Events; by deﬁnition, Adverse Reactions to Opioids
were all harmful events. CONCLUSION: IV PCA device-related
events are costly to hospitals due to their association with patient
care consequence. This study provides an innovative approach
to estimating the cost of device-related events. Additional
research is necessary to validate these ﬁndings.
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OBJECTIVES: The objective of this study was to estimate the
frequency and cost of medication errors associated with intra-
venous patient-controlled analgesia (IV PCA) from the perspec-
tive of a hospital or integrated health-system. METHODS: This
study utilized a quasi-cost accounting methodology to estimate
the costs attributable to both harmful and non-harmful IV PCA
errors. Data for the study were obtained from the MEDMARX®
dataset, published literature, and expert opinions. MEDMARX
is an anonymous error-reporting database maintained by the
United States Pharmacopeia. The database accepts multiple
inputs of error causes and error consequences per event (i.e.,
error cause and consequence categories not mutually exclusive).
The level of care rendered was estimated by applying clinical
assumptions (validated by an expert advisory panel) to each 
A175Abstracts
of the seven error consequence categories recorded in the
MEDMARX dataset. Both variable and opportunity costs (2006
values) were considered, including medication, laboratory, lost
revenue, and labor. When a particular consequence is indicated
for an error report, the corresponding costs were applied to
derive the estimated mean cost for each error cause. RESULTS:
Between July 1, 2000 and June 30, 2005, 2356 records were
identiﬁed as IV PCA errors. The most common error causes were
human factors (79.3%) and equipment-related factors (25.1%).
The overall mean cost was $733 per event, consisting of $241
in variable costs and $491 in opportunity costs. When stratiﬁed
by error causes, errors associated with equipment-related and
communication factors were the most expensive ($1189 and
$1166). Greater than 10% of the errors resulted in patient harm
and were overwhelmingly more costly than non-harmful events
($6621 versus $55). CONCLUSION: When accounting for the
full impact of IV PCA errors, they are associated with high costs
to hospitals. This study provides an innovative approach to esti-
mating the cost of IV PCA medication errors. Additional
research is necessary to validate these ﬁndings.
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OBJECTIVES: To compare price and demand for pharmaceuti-
cals for human and companion animal markets to provide
insight into the relative importance of institutional factors or
underlying market demand in determining price and utilization
for pharmaceuticals in humans. The large majority of owners of
companion animals pay the market price for pharmaceutical
therapy. Even when pet insurance exist, insurers can charge the
expected cost of providing services. In contrast, access to health
care for humans is considered an important policy objective,
third party payment is the norm, and insurers are typically not
free to adjust for an individual’s expected costs. METHODS:
Comparative review of human and animal regulatory systems,
compilation of public estimates for R&D costs, and estimation
of linear demand curves for Etodolac in human and companion
animal markets. Prices and quantities for Etodolac are taken
from studies conducted for the United States Congress.
RESULTS: Regulatory processes for both human and pets are
similar, but human development costs are much higher due to
the greater cost of clinical trials in humans. Average cost per drug
approved are estimated at $800 Million for humans and $40
Million for pets (all prices in 2001 dollars) using similar pricing
methodologies. We estimate demand in the human market as: Q
= 4.8789 − 0.0173P (Q in millions of monthly prescriptions per
year, P in dollars). For animals the demand equation is Q =
0.7688 − 0.0061P (units as for humans). If marginal cost pricing
were instituted, elasticity of demand would be −0.016 for
humans and −0.037 for pets. CONCLUSION: Even at very low
prices, we ﬁnd evidence of less price responsiveness in human
pharmaceutical markets, suggesting that institutional factors
increase the demand for pharmaceuticals and this effect is quan-
titatively important.
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OBJECTIVES: To identify whether patients using Actiq, an oral
lozenge formulation of the powerful opioid fentanyl, have any
evidence of cancer according to administrative claims records.
The Food and Drug Administration has approved Actiq for
breakthrough cancer pain and patients without such a diagnosis
should therefore be considered off-label. METHODS: Pharmacy
claims spanning the dates 2002 until 2005 from two large Mid-
western and Southern health plans were used to identify patients
receiving at least one Actiq prescription according to National
Drug Codes. All medical claims for these patients were then
searched for any primary or benign cancer diagnosis to identify
whether the population potentially qualiﬁed for use of the drug
according to Food and Drug Administration labeling. RESULTS:
Of 1,481 patients identiﬁed with Actiq, only 399 (26.9%) had
any evidence of cancer. The remaining 1,082 patients (73.1%)
potentially received Actiq in an off-label setting. By year, the
ratio of on versus off-label users was essentially unchanged from
2002 through 2005. However, the total number of users identi-
ﬁed by year doubled from 220 in 2002 to 439 in 2005. CON-
CLUSION: The majority of Actiq prescriptions may be off-label.
Given that the drug is a powerful, habit-forming opioid, these
data suggest that the use of this drug should be considered for
speciﬁc utilization review by insurers. These data also track
recent evidence indicating that the use of these drugs has
increased rapidly in recent years. Future work should examine
whether off-label use of Actiq may be related to patient copay
or other beneﬁt design characteristics.
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OBJECTIVES: To examine family physicians’ attitudes and will-
ingness to prescribe long-acting opioids to patients with moder-
ate to severe chronic nonmalignant pain (CNMP). METHODS:
The ory of Planned Behavior (TPB) was used to examine the
underlying constructs (i.e., attitude, social inﬂuences, and per-
ceived control) believed to inﬂuence physicians’ willingness to
prescribe long-acting opioids for CNMP. Three focus groups
were conducted and a web-based survey was developed, pre-
tested, and e-mailed to 2750 Texas family physicians. A total of
64 Likert-type questions were used to assess the predictors 
of physicians’ willingness to prescribe, and 10 of these items
measured physicians’ attitudes (summed range = −90 to +90).
RESULTS: A total of 267 family physicians completed the ques-
tionnaire. The TPB model accounted for 39% (F3222 = 47.4, 
p < 0.001) of the variance in explaining physicians’ willingness
to prescribe. Most physicians (N = 179, 66%) indicated that they
were willing to prescribe long-acting opioids to their CNMP
patients. Physicians unwilling to prescribe long-acting opioids
for CNMP had an overall unfavorable attitude (Mean = −7.87,
SD = 17.43) compared to willing physicians (Mean = +9.56, SD
= 17.42). Unwilling physicians held stronger beliefs that pre-
scribing opioids would lead to patient abuse, addiction and reg-
ulatory scrutiny compared to willing physicians. A signiﬁcant
positive relationship was found between previous prescribing of
long-acting opioids and attitude (R = 0.46, p < 0.01). Respon-
dents who prescribed long-acting opioids more often were less
likely to believe that it would lead to abusive and addictive
behaviors, while those who prescribed less often were more likely
to believe that it would lead to regulatory scrutiny. CONCLU-
SION: The TPB model was a signiﬁcant predictor of physicians’
